Utama › Limfoma Sel Besar Anaplastik › New York
Kajian klinikal Limfoma Sel Besar Anaplastik di New York
5 kajian untuk Limfoma Sel Besar Anaplastik sedang mencari peserta di lokasi di New York.
Bandar di New York
Teks kajian rasmi (Bahasa Inggeris)
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medicine, New York
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- University of Rochester, Rochester
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06724237A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- dan 1 lagi
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Mei 2026 · NCT07001384A Registry for People With T-cell Lymphoma
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison
- Weill Cornell Medical Center (Data Collection Only), New York
- dan 2 lagi
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 20 Mei 2026 · NCT05978141Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
- New York Medical College, Valhalla
Mengambil pesertaFasa 2
Umur 1 hingga 39 · Semua jantina · Dikemas kini 20 Mei 2026 · NCT07013565Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.